

For Immediate Release  
Contact: Dewey Steadman  
(202) 919-4097  
ir@unither.com

**UNITED THERAPEUTICS CORPORATION TO REPORT  
FIRST QUARTER 2020 FINANCIAL RESULTS  
BEFORE THE MARKET OPENS ON WEDNESDAY, APRIL 29, 2020**

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 22, 2020: United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the market opens on Wednesday, April 29, 2020.

United Therapeutics will host a teleconference on Wednesday, April 29, 2020, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing (866) 209-9943 in the United States, with international callers dialing +1 (825) 312-2282. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing (800) 585-8367 in the United States, with international callers dialing +1 (416) 621-4642, and using access code: 1984097.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at <https://ir.unither.com/events-presentations>.

### **About United Therapeutics**

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term.

Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

### **Forward-Looking Statements**

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our

periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 22, 2020 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

\* \* \*